WCE 2018: Reduction of Urinary Oxalate by Enzymatic Reduction of Dietary and Endogenous Oxalate

A recombinant version of oxalate decarboxylase, called A0, which is being developed by Captozyme, Inc could give hope to patients with oxalosis and hyperoxaluria, according to a study presented at the World Congress of Endourology (WCE) in Paris, France. This is great news for organizations such as the The Oxalosis and Hyperoxaluria Foundation, working to help these patients.

Read more from URO TODAY.